 |
|
|
| |
In Vitro Characterization of Elebsiran (VIR-2218), an Investigational siRNA Therapeutic Targeting Hepatitis B Virus
|
| |
| |
EASL 2025 May 7-10 Amsterdam
Hasan Imam,1 Jiayi Zhou,1 Tuyen Nguyen,2 Joseph Barry,2 Adam Castoreno,2 Florian A. Lempp,1 Andrea L. Cathcart,1 Gregory Camus1
1Vir Biotechnology, Inc., San Francisco, CA, USA; 2Alnylam Pharmaceuticals, Cambridge, MA, USA.
EASL: Outcomes of 48 Weeks of Therapy and Subsequent 24-Week Post-Treatment Period With Tobevibart (VIR-3434) and Elebsiran (VIR-2218) With or Without Pegylated Interferon Alfa-2a in Chronic Hepatitis B Virus Infection: Findings From the MARCH Study - (05/12/25)
|
| |
|
|
|
|
|
